Key takeaways
- ~$300K approximate annual cost of IV enzyme replacement therapy per Gaucher patient, Part B buy-and-bill
- $310,250 eliglustat (Cerdelga) launch annual WAC, dispensed through Part D
- 3 IV ERT brands, none generic; preferred-vs-non-preferred designation functions as the pricing lever
- Generic miglustat (Zavesca) status; payers require a documented trial first before other oral options
Preferred-ERT designation, a genotype prior-authorization gate, and generic substitution, not head-to-head price competition, are the levers that actually move Gaucher pricing.
The three IV enzyme replacement therapies for Gaucher type 1, imiglucerase, velaglucerase alfa, and taliglucerase alfa, are physician-administered infusions billed through the Medicare Part B medical benefit under buy-and-bill, at an approximate annual cost of $300,000 per patient. None of the three faces generic competition, so payers extract pricing leverage a different way: several designate imiglucerase and velaglucerase alfa as preferred ERT, positioning taliglucerase alfa as the non-preferred alternative, a designation that functions as a de facto rebate and negotiation signal even without published net-price data.
Eliglustat (Cerdelga), the oral substrate reduction alternative, launched in 2014 at an annual wholesale acquisition cost of $310,250 and dispenses through the Part D pharmacy benefit rather than Part B. Its prior authorization requires documented CYP2D6 extensive, intermediate, or poor metabolizer status by an FDA-cleared genotype test, a built-in utilization-management lever absent from the IV therapies. Miglustat (Zavesca), now available generically, sits at the bottom of the pricing ladder, and payers increasingly require a documented trial of generic miglustat before authorizing any other oral option, anchoring the low end of the market with a generic-substitution lever rather than a rebate negotiation.
US Gaucher type 1 pricing — five agents, three distinct pricing levers
| Drug (Brand / INN) | Mechanism / Route | Benefit Routing | Approx. Annual Cost | Pricing Lever |
|---|---|---|---|---|
| Cerezyme (imiglucerase) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Often designated preferred ERT |
| VPRIV (velaglucerase alfa) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Frequently designated preferred ERT |
| Elelyso (taliglucerase alfa) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Typically non-preferred alternative |
| Cerdelga (eliglustat) | Oral substrate reduction | Medicare Part D | $310,250 WAC | CYP2D6 genotype prior-authorization gate |
| Zavesca (miglustat) | Oral substrate reduction | Medicare Part D | Generic available | Generic-first trial requirement |
Sources: UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025-2026); Cerdelga launch WAC per Boston Globe 2014; FDA prescribing information (Cerdelga, Zavesca); FDA Drugs@FDA.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does preferred-versus-non-preferred ERT designation function as a pricing lever when none of the three brands faces generic competition? • Preferred/non-preferred designation mechanics • what the designation implies about underlying rebate structure • contracting implications for a new IV entrant
- What does eliglustat's CYP2D6 genotype gate mean for a pricing and access strategy on Part D? • WAC-to-net-price considerations under Part D • CYP2D6 prior-authorization gate mechanics • utilization-management implications for an oral entrant
- How does generic miglustat anchor the low end of the market, and what does a generic-first requirement mean for a new oral entrant? • Generic miglustat's role as the market's price floor • the generic-first trial requirement • competitive pricing implications for a new substrate reduction therapy
What's inside
-
1 · The Binding Constraint 2 pp
- Why preferred-ERT designation, a genotype gate, and generic substitution decide pricing power here, not head-to-head price competition
- Pressure-tested against the current five-drug standard of care before the rest of the model is built out
-
2 · Price Ladder — IV ERT Annual Cost & Part B Routing 3 pp
- The ~$300,000 annual cost of imiglucerase, velaglucerase alfa, and taliglucerase alfa under Part B buy-and-bill
- Why none of the three ERTs faces generic competition
-
3 · Preferred vs Non-Preferred ERT Designation 3 pp
- How payers designate imiglucerase and velaglucerase alfa as preferred, positioning taliglucerase alfa as the alternative
- What the designation implies about rebate structure absent published net-price data
-
4 · Eliglustat's CYP2D6 Genotype Gate & Part D Routing 3 pp
- The $310,250 launch WAC and Part D pharmacy-benefit routing
- The CYP2D6 extensive/intermediate/poor metabolizer prior-authorization gate
-
5 · Generic Miglustat & the Trial-First Requirement 3 pp
- Miglustat's generic status anchoring the low end of the oral market
- The generic-first utilization-management requirement payers increasingly apply
-
6 · GTN Waterfall & Contracting Options 3 pp
- Net-price scenarios built against the preferred/non-preferred designation and genotype-gate levers
- Contracting structures a new entrant could propose to secure preferred status
-
7 · Launch Sequencing & Revenue Scenarios 4 pp
- Conservative, base, and aggressive revenue scenarios by channel (Part B IV vs Part D oral)
- Budget-impact framing given the market's mature orphan-pricing structure
-
8 · Client Alignment Questions 2 pp
- The open pricing questions your team must close before a launch price is locked
- Structured for an internal pricing committee session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers Gaucher disease pricing strategy models built for market access and pricing teams navigating preferred-ERT designation, the CYP2D6 gate, and generic miglustat dynamics. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, market basket, and comparator scope.
- 2. Scoping callAXLRx analyst confirms pricing mechanism assumptions and payer set before building.
- 3. DeliveryResearch-verified pricing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx pricing model is built from primary sources, FDA regulatory documentation, live payer medical and pharmacy coverage policies, and contemporaneous pricing reporting, not secondary summaries. Findings are independently verified before inclusion.
Gaucher disease US pricing sources: UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025-2026), Cerdelga and Zavesca FDA prescribing information, and contemporaneous WAC reporting (Boston Globe 2014).
- IV ERT annual cost (~$300,000) and Part B buy-and-bill routing verified against payer medical coverage policies and CMS benefit-classification rules
- Preferred-vs-non-preferred ERT designation verified against UnitedHealthcare and Blue Cross Blue Shield Gaucher coverage policies (2025-2026)
- Eliglustat's $310,250 launch WAC and CYP2D6 genotype prior-authorization gate verified against Boston Globe 2014 reporting and the Cerdelga FDA prescribing information
- Miglustat's generic status and the generic-first trial requirement verified against payer pharmacy coverage policies
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Pricing Strategy Model includes an editable 12-sheet Excel model (Price Ladder, Preferred-ERT Designation, Value-Based ICER, GTN Waterfall, Launch Sequencing, Revenue Scenarios, Sensitivity, Payer Landscape, QC, Sources) and a PDF methodology brief, no PowerPoint deck, since a pricing model is built to be worked in directly rather than presented from. An optional 45-minute analyst readout call is included.
Sources How is the pricing evidence verified?
AXLRx builds from primary sources only, FDA regulatory documentation, live payer medical and pharmacy coverage policies, and contemporaneous pricing reporting. Every reference price, designation, and utilization-management gate is independently verified before inclusion.
Customisation Can I model a specific payer's coverage policy or comparator set?
Yes. The intake form captures your indication, target payer set, and comparator class. A scoping call confirms scope before research starts. Commission via the intake form to start.